Bumetanide
As of the edition of 20 October 2026, Bumetanide is a small molecule: marketed, first approved in 1974 (ES); acts on SLC12A1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1986
- Kind
- Small molecule
- Brand name
- Bumex
- First approved
- 1 January 1974 (ES)
- Approvals on record
- 7 in 3 regions
- Holder of the most recent approval
- Corstasis Therapeutics; 4 holders in all
- Registered trials
- 24, 8 stopped early
- Disease areas
- Heart and blood vessels; Mental health; Nervous system; Pregnancy and women's health; Urinary and reproductive; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Bumetanide.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC12A1 | Solute carrier family 12 member 1 | Q13621 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 1 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 9 | 5 | 2 | 2 |
| Phase 3 | 5 | 1 | 2 | 2 |
| Phase 4 | 7 | 3 | 0 | 3 |
| All trials | 24 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Roche | Earlier holder | 1983 to now |
| Validus Pharmaceuticals | Acquired holder | 2017 to now |
| Corstasis Therapeutics | Later holder | 2025 to now |